{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=12", "query": { "intervention": "Reference product", "page": 12 }, "page_size": 10 }, "pagination": { "page": 12, "page_size": 10, "total_count": 362, "total_pages": 37, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=13&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Reference+product&page=11&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-02T10:56:43.541Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02417129", "title": "BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "BI 695500", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 2, "start_date": "2015-04", "completion_date": "2015-12", "has_results": true, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-11-02T10:56:43.541Z", "location_count": 13, "location_summary": "Muscle Shoals, Alabama • Bakersfield, California • Burbank, California + 10 more", "locations": [ { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Bakersfield", "state": "California" }, { "city": "Burbank", "state": "California" }, { "city": "Loma Linda", "state": "California" }, { "city": "Albany", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02417129" }, { "nct_id": "NCT05848713", "title": "AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Community-acquired Pneumonia" ], "interventions": [ { "name": "Heparin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Manitoba", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4000, "start_date": "2023-10-10", "completion_date": "2029-03-31", "has_results": false, "last_update_posted_date": "2026-09-30", "last_synced_at": "2026-11-02T10:56:43.541Z", "location_count": 6, "location_summary": "Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Jefferson", "state": "Louisiana" }, { "city": "Portland", "state": "Maine" }, { "city": "Dearborn", "state": "Michigan" }, { "city": "Camden", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05848713" }, { "nct_id": "NCT03179605", "title": "Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Psoriasis" ], "interventions": [ { "name": "DFD06", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Primus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 22, "start_date": "2017-05-02", "completion_date": "2020-06-03", "has_results": true, "last_update_posted_date": "2024-03-07", "last_synced_at": "2026-11-02T10:56:43.541Z", "location_count": 9, "location_summary": "Madera, California • Santa Ana, California • Hialeah, Florida + 5 more", "locations": [ { "city": "Madera", "state": "California" }, { "city": "Santa Ana", "state": "California" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Hialeah", "state": "Florida" }, { "city": "Overland Park", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03179605" }, { "nct_id": "NCT02823171", "title": "To Assess the Bioequivalence of Two Pacritinib Drug Product Formulations and FMI Formulation Following Oral Administration in Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Treatment A: 400 mg Pacritinib P3CT", "type": "DRUG" }, { "name": "Treatment B: 400 mg of pacritinib FMI", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CTI BioPharma", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 28, "start_date": "2015-08", "completion_date": "2015-09", "has_results": false, "last_update_posted_date": "2023-09-15", "last_synced_at": "2026-11-02T10:56:43.541Z", "location_count": 1, "location_summary": "Evansville, Indiana", "locations": [ { "city": "Evansville", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT02823171" }, { "nct_id": "NCT07285148", "title": "A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-Small Cell Lung Cancer", "EGFR Mutation", "Metastatic Lung Cancer", "MET Alteration" ], "interventions": [ { "name": "ANS014004 + PLB1004", "type": "DRUG" }, { "name": "ANS014004 + Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Beijing Pearl Biotechnology Limited Liability Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 253, "start_date": "2026-06", "completion_date": "2029-12", "has_results": false, "last_update_posted_date": "2025-12-16", "last_synced_at": "2026-11-02T10:56:43.541Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07285148" }, { "nct_id": "NCT00840411", "title": "Clarithromycin 500 mg Extended Release Tablets Under Fasting Conditions", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "Clarithromycin ER 500 mg tablets", "type": "DRUG" }, { "name": "BIAXIN® XL 500 mg tablets", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Teva Pharmaceuticals USA", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 66, "start_date": "2002-09", "completion_date": "2002-10", "has_results": true, "last_update_posted_date": "2024-08-19", "last_synced_at": "2026-11-02T10:56:43.541Z", "location_count": 1, "location_summary": "Saint Charles, Missouri", "locations": [ { "city": "Saint Charles", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT00840411" }, { "nct_id": "NCT01517399", "title": "Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "tivantinib", "type": "DRUG" }, { "name": "omeprazole", "type": "DRUG" }, { "name": "s-warfarin", "type": "DRUG" }, { "name": "caffeine", "type": "DRUG" }, { "name": "vitamin K", "type": "DIETARY_SUPPLEMENT" }, { "name": "digoxin", "type": "DRUG" }, { "name": "midazolam", "type": "DRUG" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Daiichi Sankyo", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 28, "start_date": "2011-12", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2019-02-12", "last_synced_at": "2026-11-02T10:56:43.541Z", "location_count": 1, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01517399" }, { "nct_id": "NCT01289509", "title": "A Study to Evaluate the Relative Bioavailability and Intra-Subject Variability of Two Lots of E5501 40 mg Tablets Administered Twice as Single Oral Doses to Healthy Subjects", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Idiopathic Thrombocytopenia Purpura" ], "interventions": [ { "name": "E5501", "type": "DRUG" }, { "name": "Drug: E5501", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 42, "start_date": "2010-12", "completion_date": "2011-05", "has_results": false, "last_update_posted_date": "2013-11-01", "last_synced_at": "2026-11-02T10:56:43.541Z", "location_count": 1, "location_summary": "Lenexa, Kansas", "locations": [ { "city": "Lenexa", "state": "Kansas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01289509" }, { "nct_id": "NCT03528577", "title": "A Study to Evaluate the Effect of of Albuterol Sulfate Inhalation Aerosol, eq 90 mcg Base (Sun Pharmaceuticals Industries Limited)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "Zero-dose", "type": "DRUG" }, { "name": "90 mcg of PROAIR® HFA", "type": "DRUG" }, { "name": "180 mcg of 90 mcg of PROAIR® HFA", "type": "DRUG" }, { "name": "90 mcg of albuterol sulfate inhalation aerosol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sun Pharmaceutical Industries Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 128, "start_date": "2018-09-22", "completion_date": "2019-08-03", "has_results": true, "last_update_posted_date": "2021-01-22", "last_synced_at": "2026-11-02T10:56:43.541Z", "location_count": 8, "location_summary": "Miami Lakes, Florida • Bethesda, Maryland • St Louis, Missouri + 5 more", "locations": [ { "city": "Miami Lakes", "state": "Florida" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Gastonia", "state": "North Carolina" }, { "city": "Edmond", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT03528577" }, { "nct_id": "NCT03324061", "title": "Study to Evaluate the Safety, Tolerability, and PK of Fulvestrant After IM Administration", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pharmacokinetics" ], "interventions": [ { "name": "Fulvestrant for Injectable Suspension", "type": "DRUG" }, { "name": "Faslodex (Reference)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eagle Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "40 Years", "maximum_age": "75 Years", "sex": "FEMALE", "summary": "40 Years to 75 Years · Female only" }, "enrollment_count": 600, "start_date": "2017-11-30", "completion_date": "2018-07-12", "has_results": false, "last_update_posted_date": "2021-06-03", "last_synced_at": "2026-11-02T10:56:43.541Z", "location_count": 12, "location_summary": "Long Beach, California • DeLand, Florida • Miami, Florida + 7 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "DeLand", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03324061" } ] }